prnewswire.com
More than 70 percent of 200 patients with mild to moderate sleep apnea participating in a Qualtrics Survey conducted September 4 though September 11 selected the FDA-approved Bongo Rx as their preferred choice over a traditional CPAP.
Unlike the bulky CPAP machine, the Bongo Rx is a small, discrete nasal device that does not require hoses or an external machine.
"I feel the results of this Qualtrics Survey reflect that mild to moderate Obstructive Sleep Apnea (OSA) sufferers want a simple and effective alternative to traditional CPAP machines from companies such as ResMed, Phillips Respironics and Fisher & Paykel Health Care Corporation Limited," Bruce Sher, President of AirAvant Medical, maker of the Bongo Rx, said in a press release. "Over 70 percent of the respondents in this survey chose Bongo Rx. It's gratifying that years of effort by our team to develop the Bongo Rx have yielded such a great outcome."
Industry experts believe that approximately 50 percent of CPAP users will stop using their CPAP machines in favor of the Bongo Rx.
AirAvant is a research-oriented, privately held company focused on the development and marketing of new medical devices to treat OSA. The company includes partners from InnoMed Technologies, Inc. and Ron F. Richard from ResMed and SeQual Technologies.
